A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV 16 Positive Oropharynx Cancer

ID Number 12-1050

Principal Investigator(s)
Marshall Posner

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to compare two doses of radiation therapy (reduced vs standard) with weekly chemotherapy.

HPV related Oropharynx cancer (HPVOPC) accounts for 60% of oropharynx cancer cases in United States. HPVOPC has better prognosis than patients with HPV negative oropharynx cancer. Even though survival rate has increased because of chemoradiation therapy (CRT), the long term side effects of radiation therapy are still problematic. There are no current randomized trials of reduced dose radiotherapy for HPVOPC. In this trial by comparing reduced with standard dose of radiotherapy after using chemotherapy as initial treatment for cancer (induction chemotherapy), we are proposing that by selecting reduced radiotherapy intensity, we can reduce the long term consequences and preserve the survival.

You may qualify to take part in this research study because you are diagnosed with head and neck cancer which is tested positive for HPV 16 and p16 and not have received any prior chemotherapy or radiotherapy or surgery for your cancer.

Contact Information

Recruiting Patients: No